Literature DB >> 24381160

Role for terminal complement activation in amyotrophic lateral sclerosis disease progression.

Trent M Woodruff1, John D Lee, Peter G Noakes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24381160      PMCID： PMC3890900          DOI： 10.1073/pnas.1321248111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  5 in total

1.  C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice.

Authors:  Christian S Lobsiger; Severine Boillée; Christine Pozniak; Amir M Khan; Melissa McAlonis-Downes; Joseph W Lewcock; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

2.  Generation of C5a in the absence of C3: a new complement activation pathway.

Authors:  Markus Huber-Lang; J Vidya Sarma; Firas S Zetoune; Daniel Rittirsch; Thomas A Neff; Stephanie R McGuire; John D Lambris; Roscoe L Warner; Michael A Flierl; Laszlo M Hoesel; Florian Gebhard; John G Younger; Scott M Drouin; Rick A Wetsel; Peter A Ward
Journal:  Nat Med       Date:  2006-05-21       Impact factor: 53.440

3.  The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis.

Authors:  Trent M Woodruff; Kerina J Costantini; James W Crane; Julie D Atkin; Peter N Monk; Stephen M Taylor; Peter G Noakes
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

4.  Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis.

Authors:  Dale Pavlovski; John Thundyil; Peter N Monk; Rick A Wetsel; Stephen M Taylor; Trent M Woodruff
Journal:  FASEB J       Date:  2012-05-31       Impact factor: 5.191

5.  Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  John D Lee; Nur A Kamaruzaman; Jenny N T Fung; Stephen M Taylor; Bradley J Turner; Julie D Atkin; Trent M Woodruff; Peter G Noakes
Journal:  J Neuroinflammation       Date:  2013-09-26       Impact factor: 8.322
  5 in total
  18 in total

Review 1.  Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis.

Authors:  Kristopher G Hooten; David R Beers; Weihua Zhao; Stanley H Appel
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

2.  Reply to Woodruff et al.: C1q and C3-dependent complement pathway activation does not contribute to disease in SOD1 mutant ALS mice.

Authors:  Christian S Lobsiger; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-07       Impact factor: 11.205

3.  Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis.

Authors:  John D Lee; Vinod Kumar; Jenny N T Fung; Marc J Ruitenberg; Peter G Noakes; Trent M Woodruff
Journal:  Br J Pharmacol       Date:  2017-03-03       Impact factor: 8.739

4.  Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.

Authors:  Anna Gaimari; Michele Fusaroli; Emanuel Raschi; Elisa Baldin; Luca Vignatelli; Francesco Nonino; Fabrizio De Ponti; Jessica Mandrioli; Elisabetta Poluzzi
Journal:  Drug Saf       Date:  2022-05-24       Impact factor: 5.606

Review 5.  The emerging role of complement in neuromuscular disorders.

Authors:  John D Lee; Trent M Woodruff
Journal:  Semin Immunopathol       Date:  2021-10-27       Impact factor: 9.623

Review 6.  Aberrant Complement System Activation in Neurological Disorders.

Authors:  Karolina Ziabska; Malgorzata Ziemka-Nalecz; Paulina Pawelec; Joanna Sypecka; Teresa Zalewska
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

7.  Neuron-specific antioxidant OXR1 extends survival of a mouse model of amyotrophic lateral sclerosis.

Authors:  Kevin X Liu; Benjamin Edwards; Sheena Lee; Mattéa J Finelli; Ben Davies; Kay E Davies; Peter L Oliver
Journal:  Brain       Date:  2015-03-09       Impact factor: 13.501

8.  Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis.

Authors:  Jia Y Lee; John D Lee; Simon Phipps; Peter G Noakes; Trent M Woodruff
Journal:  J Neuroinflammation       Date:  2015-05-13       Impact factor: 8.322

Review 9.  Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases.

Authors:  Falguni Baidya; Mariya Bohra; Aishika Datta; Deepaneeta Sarmah; Birva Shah; Priya Jagtap; Swapnil Raut; Ankan Sarkar; Upasna Singh; Kiran Kalia; Anupom Borah; Xin Wang; Kunjan R Dave; Dileep R Yavagal; Pallab Bhattacharya
Journal:  Immunology       Date:  2020-10-06       Impact factor: 7.397

10.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.